CAS NO. |
Products Name |
1047634-65-0 |
GSK2141795 |
more... |
GSK2141795 is a potent and selective pan-Akt inhibitor with IC50 values of 180 nM for Akt1, 328 nM for Akt2, and 38 nM for Akt3 respectively (Clinical phase 1). |
|
305834-79-1 |
sc79 |
more... |
SC79 is a unique specific Akt activator that may be used to enhance Akt activity in various physiological and pathological conditions. |
|
866405-64-3 |
BML-275 |
more... |
Dorsomorphin(Compound C; BML-275) has been shown to act as a potent and selective inhibitor of AMPK (AMP-activated protein kinase; Ki = 109 nM), induced by AICAR and metformin; also inhibits the bone morphogenetic protein type 1 receptors ACTR-I (ALK2), BMPR-IA (ALK3), and BMPR-IB (ALK 6). |
|
95167-41-2 |
DY-131 |
more... |
DY131(GSK 9089) is a novel selective agonist of ERRβ and ERRγ; displays minimal activity at ERRα, ERα and ERβ at concentrations up to 30 μM. |
|
1550008-55-3 |
ML264 |
more... |
ML 264 is a potent Krüppel-like factor 5 (KLF5) inhibitor. ML264 inhibits the MAPK pathway by reducing EGR1 and KLF5 levels. ML 264 decreases proliferation of colorectal cancer cell lines, and inhibits the growth of xenografts in a mouse model of primary tumor development. |
|
361185-42-4 |
RBC8 |
more... |
RBC8 is a novel small molecule inhibitor of Ral GTPase; has IC50 of 3.5 μM in H2122 cell and 3.4 μM in H358 cell. |
|
1236699-92-5 |
AS703026 |
more... |
AS703026(Pimasertib) is a highly selective, potent, ATP non-competitive allosteric inhibitor of MEK1/2 with IC50 of 5 nM-2 μM in MM cell lines. |
|
146464-95-1 |
Pralatrexat |
more... |
Pralatrexate(Folotyn) is an antifolate, and structurally a folate analog. Its IC50 is < 300 nM in some cell lines. |
|
|
130495-35-1 |
SKF96365 hcl |
more... |
SKF-96365, an SOCE inhibitor, exhibits potent anti-neoplastic activity by inducing cell-cycle arrest and apoptosis in colorectal cancer cells.[1] SKF-96365 can induces cytoprotective autophagy to delay apoptosis by preventing the release of cytochrome c (cyt c) from the mitochondria into the cytoplasm. |
|
|
|